TY - JOUR
T1 - Convergence Insufficiency Neuro-mechanism in Adult Population Study Randomized Clinical Trial
T2 - Clinical Outcome Results
AU - Alvarez, Tara L.
AU - Scheiman, Mitchell
AU - Santos, Elio M.
AU - Yaramothu, Chang
AU - D'Antonio-Bertagnolli, John Vito
N1 - Funding Information:
The Convergence Insufficiency Neuro-mechanism in Adult Population Study was supported by the National Eye Institute of the National Institutes of Health and conducted according to the tenets of the Declaration of Helsinki. The institutional review board of the New Jersey Institute of Technology and Rutgers University approved the protocol and the informed consent forms. Each study participant gave written informed consent. The study is registered at ClinicalTrials.gov as Neural Mechanism of Vision Therapy for Patients with Convergence Insufficiency: NCT03593031. The Convergence Insufficiency Neuro-mechanism in Adult Population Study is a longitudinal double-masked randomized clinical trial study. The complete protocol is available in a previous publication.11,12 Herein, we summarize the most relevant portions of the protocol.
Publisher Copyright:
© Lippincott Williams & Wilkins.
PY - 2020/12
Y1 - 2020/12
N2 - SIGNIFICANCE These data confirm the effectiveness of office-based vergence/accommodative therapy for improving the near point of convergence and positive fusional vergence in young adults with symptomatic convergence insufficiency within a double-masked longitudinal randomized clinical trial. PURPOSE This study aimed to report changes in clinical signs and symptoms of convergence insufficiency from a randomized clinical trial evaluating the effectiveness of office-based vergence/accommodative therapy for young adults with symptomatic convergence insufficiency. METHODS In this double-masked, randomized clinical trial, convergence insufficiency patients (n = 50; average age, 21 ± 3 years; range, 18 to 32 years) were randomized to either office-based vergence/accommodative therapy or office-based placebo therapy. Improvements in (1) near point of convergence, (2) positive fusional vergence, and (3) self-reported symptoms (Convergence Insufficiency Symptom Survey [CISS] score) were evaluated after twelve 1-hour sessions of treatment within the office comparing the results from the vergence/accommodative therapy and the placebo therapy groups. RESULTS The mean near point of convergence improved by 6.0 and 3.1 cm in the vergence/accommodative and placebo therapy groups, respectively (mean difference of -2.9 cm; 95% confidence interval [CI], -4.6 to -1.0 cm; P <.01). The mean positive fusional vergence increased by 17.3 and 7.4Δ in the vergence/accommodative and placebo therapy groups, respectively (mean difference of 9.9Δ; 95% CI, 4.9 to 16.0Δ; P <.001). The mean CISS score improved by 12.4 and 10.1 points in the vergence/accommodative and placebo therapy groups, respectively (mean difference of 2.3 points; 95% CI, -8.3 to +4.6 points; P =.56). CONCLUSIONS Our results demonstrate that office-based vergence/accommodative therapy is effective for improving the near point of convergence and positive fusional vergence in young adults with symptomatic convergence insufficiency. However, given that both treatment groups had a similar reduction in self-reported symptoms, we recommend that the CISS be revised if it is to be used as an outcome measure in future studies of convergence insufficiency.
AB - SIGNIFICANCE These data confirm the effectiveness of office-based vergence/accommodative therapy for improving the near point of convergence and positive fusional vergence in young adults with symptomatic convergence insufficiency within a double-masked longitudinal randomized clinical trial. PURPOSE This study aimed to report changes in clinical signs and symptoms of convergence insufficiency from a randomized clinical trial evaluating the effectiveness of office-based vergence/accommodative therapy for young adults with symptomatic convergence insufficiency. METHODS In this double-masked, randomized clinical trial, convergence insufficiency patients (n = 50; average age, 21 ± 3 years; range, 18 to 32 years) were randomized to either office-based vergence/accommodative therapy or office-based placebo therapy. Improvements in (1) near point of convergence, (2) positive fusional vergence, and (3) self-reported symptoms (Convergence Insufficiency Symptom Survey [CISS] score) were evaluated after twelve 1-hour sessions of treatment within the office comparing the results from the vergence/accommodative therapy and the placebo therapy groups. RESULTS The mean near point of convergence improved by 6.0 and 3.1 cm in the vergence/accommodative and placebo therapy groups, respectively (mean difference of -2.9 cm; 95% confidence interval [CI], -4.6 to -1.0 cm; P <.01). The mean positive fusional vergence increased by 17.3 and 7.4Δ in the vergence/accommodative and placebo therapy groups, respectively (mean difference of 9.9Δ; 95% CI, 4.9 to 16.0Δ; P <.001). The mean CISS score improved by 12.4 and 10.1 points in the vergence/accommodative and placebo therapy groups, respectively (mean difference of 2.3 points; 95% CI, -8.3 to +4.6 points; P =.56). CONCLUSIONS Our results demonstrate that office-based vergence/accommodative therapy is effective for improving the near point of convergence and positive fusional vergence in young adults with symptomatic convergence insufficiency. However, given that both treatment groups had a similar reduction in self-reported symptoms, we recommend that the CISS be revised if it is to be used as an outcome measure in future studies of convergence insufficiency.
UR - http://www.scopus.com/inward/record.url?scp=85098603198&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85098603198&partnerID=8YFLogxK
U2 - 10.1097/OPX.0000000000001606
DO - 10.1097/OPX.0000000000001606
M3 - Article
C2 - 33186192
AN - SCOPUS:85098603198
SN - 1040-5488
VL - 97
SP - 1061
EP - 1069
JO - American Journal of Optometry and Physiological Optics
JF - American Journal of Optometry and Physiological Optics
IS - 12
ER -